J P Moulton Charitable Foundation

Jon Moulton photo


The J P Moulton Charitable Foundation was founded by Jon Moulton in 2004 with the goal of promoting clinical research throughout the UK. Before founding the J P Moulton Charitable Foundation, Jon Moulton made personal contributions and was one of the fundrasing boards. However, he believed that he could help fund a wider spectrum of research and has already pledged over £20 million pounds to many different trials across the medical field. 

Some of the gains from investments that Perscitus has advised are indirectly used to fund donations from this Charity.


Principal Aim

To fund non-commercial clinical trials with the aim to make clinical advances and promote the relief of suffering (main activity)


Clinical Research Awards

Since its inception the charity has funded over 100 clinical trials which have been selected based on high quality science with the potential to have a direct benefit to patients. The trials have been conducted in a wide range of therapy areas including respiratory, women’s health, oncology, cardiovascular, diabetes, multiple sclerosis, several rare diseases, COPD, paediatrics and the funded trials are usually interventional. 

The charity has supported ground-breaking research in diseases that struggle to obtain funding from other funders as they do not fulfil their funding criteria e.g. head and neck cancer and rare diseases. The Foundation has also entered into several joint ventures with other medical charities to help support larger trials.


How to Apply for Funding

Calls for funding are advertised in the Lancet and BMJ periodically. 

Please note that successful new applications will be funded by The Jon Moulton Charity Trust, a new Jon Moulton charity established in Guernsey in 2018.

Applications should initially be no more than 12 pages in length and they should outline the following:-

  • Research title
  • Contact details for the lead applicant
  • The background and rationale for the trial
  • The expertise and experience of the applicants
  • A summary protocol including details of any devices, investigational medicinal products and statistical calculations
  • A detailed budget and justification of costs
  • A firm timescale for the duration of the trial – including realistic set-up, recruitment and analysis periods
  • Any ethical or conflicts of interest issues
  • Possible and desired outcomes
  • Applicants will receive a decision approximately 6 weeks (often quicker) after the submission deadline.
  • Awardees will be expected to provide a final budget with calendarisation of expenditure
  • Quarterly progress reports are required every quarter

Confirmation in writing to the Trustees that:-

  • All findings from your trials will be made available for publication and efforts will be made for publication.
  • No intellectual property generated from the trial will be retained for commercial exploitation.

Approximately 20% of applications receive full or partial funding and the charity has provided over £20 million in funding since 2004. Researchers have published well over 100 articles as a direct result of the funding awarded by the Foundation.


Funding Calls

The Foundation advertised in late 2017 for applications for funding for clinical trials in the UK. 74 applications covering some £34 million were received by the closing date of 22nd September. Many of these applications were of exceptional quality and the overall standard high. The Trustees have now agreed to provide in excess of £5 million to fund 16 of these trials which cover a wide spread of therapy areas.



Examples of publications resulting from funding can be accessed below:-

Gene-environment interactions in the development of asthma and atopy - read more

Does the addition of subcutaneous interferon-alpha 2b for 6 months only to the treatment of Behcet's disease significantly reduce the number of patients requiring immunosuppressive agents to control their disease over the following 2 years - read more

Randomised, placebo-controlled trial of itraconazole in the treatment of Fungal-sensitised patients with severe asthma without ABPA - read more and read more

A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3 - read more

Gastro-oesophageal reflux disease in chronic cough: a randomised control trial of medical versus surgical treatments - read more and read more and read more

A randomised trial of botulinum toxin A versus placebo for refractory detrusor over-activity - RELAX study - read more

AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India - read more

Phase II trial of autologous dentritic cells transfected with a plasmid encoding melanocyte differentiation antigens using a non-viral delivery system for the treatment of patients with metastatic melanoma  - read more

The effect of thalidomide on cachexia in upper gastrointestinal cancer - read more 

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients  - read more

Cranberry product versus low does trimethoprim in the prevention of recurrent urinary infections in older women - read more

Does remote ischaemic preconditioning reduce complications following major vascular surgery - read more

Repair of Spinal Root Injury by Transplantation of Autologous Adult Olfactory Ensheathing Cells - read more

Atorvastatin for preventing the progression of sepsis to severe sepsis (ASEPSIS Trial): a randomised, double-blind, placebo-controlled trial - read more

A phase I/II clinical study of gene modified donor lymphocytes following haploidentical haematopoietic stem cell transplantation - read more

Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis (MS-STAT) - read more

Genetic factors and gene-environment interactions in the onset, persistence and severity of asthma - read moreread more

The Epistasis Project - read more and read more and read more and read more

Scavenging free haemoglobin attenuates the systemic inflammation response following surgery - read more

Comparison of high flow versus titrated oxygen therapy in the emergency department management of St Elevation Myocardial Infarction Trial - OPTIMISE study - read more

Cognitive function and surgical success following pulmonary endarterectomy - The PEACOG trial - read more

Vitamin D and skeletal muscle weakness in chronic obstructive pulmonary disease - read more

Superdose project - a community study investigating a dose relationship between neonatal BCG vaccination and risk of asthma and atopy in children - MANCAS Study - read more

A randomised controlled trial of laparoscopic adhesiolysis on chronic pelvic pain - read more

A randomised controlled trial of prednisolone for women with recurrent miscarriage and high levels of uNK cells in the endometrium - read more

Muscle MRI in Congenital Myasthenia - read more

Lenviral Gene Therapy for inherited skin disease: Phase 1 testing of ex-vivo gene modified skin grafts in Netherton Syndrome - read more and read more

Is diabetes surgery effective and safe for the treatment of Type 2 Diabetes Mellitus? - read more and read more and read more and read more and read more

Susceptibility to infections and exacerbations of asthma: makers and mechanisms - read more

Avoiding mite allergen to prevent asthma exacerbations in children - read more

Duration of Luteal Support with progesterone pessaries to improve success rates in assisted conception; a randomised controlled trial. (The DOLS Trial) - read more

Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene - read more

Contact Details

For any enquiries please contact Helen Critchley via email:- helen@jpmfoundation.co.uk

or in writing:-

Jon Moulton

c/o J P Moulton Charitable Foundation

10 Buckingham Street




Charity Number 1109891